Seth Inzaule awarded doctorate degree 'Cum Laude' for HIV.
Background Human immunodeficiency virus (HIV), multi-drug resistant tuberculosis (MDR) is emerging as major challenge facing tuberculosis control programs worldwide particularly in Asia and Africa. Findings from different studies on associations of HIV co-infection and drug resistance among patients with TB have been contradictory (discordant). Some institution based studies found strongly.
Editorial Board Members. The HIV Drug Interactions website has been in operation since 1999. The website team is based at the University of Liverpool and has responsibility to constantly monitor and update the site’s content. In 2009 an Editorial Board was established to provide oversight, strategic vision and direction for the site. It also advises on developmental opportunities and the.
The Stanford University HIV Drug Resistance Database also provides helpful guidance for interpreting genotypic resistance test results. 1 Various additional tools are also available to assist providers in interpreting genotypic test results. 2-5 Clinical trials have demonstrated that consulting with specialists in HIV drug resistance improves virologic outcomes. 6 Clinicians are thus.
Background: Little is known about the long term risk of development of HIV-1 drug resistance for patients starting antiretroviral therapy (ART) with three or four drug regimens in routine clinical.
HIVseq Program. Literature Prevalence of Mutations in Submitted Sequences. HIVseq accepts user-submitted RT, protease, and integrase sequences or mutations. Translated sequences are compared to the consensus subtype B reference sequence and the differences are used as query parameters for interrogating the HIV Drug Resistance Database to determine the prevalence of each mutation in.
Transmitted drug resistance. One consequence of a high prevalence of drug-resistant HIV-1 is the risk that such viruses will be transmitted. A study conducted at sentinel HIV-1 testing sites by the US Centers for Disease Control and Prevention (CDC) found the overall prevalence of antiretroviral drug resistance mutations in samples from persons newly diagnosed with HIV-1 infection during 1997.
HIV drug resistance is helpful in guiding individual clinical decisions and the development of ARV treatment guidelines. 1. Introduction The development of antiretroviral (ARV) com- binations potent enough to prevent the emergence of HIV-1 drug resistance was central to the devel-opment of successful ARV therapy (ART). None-theless, the acquisition and transmission of HIV-1 drug resistance.